Genenta to present at upcoming scientific congresses ASGCT – ASCO – EHA

May 10, 2021

MILAN (Italy) / NEW YORK (NY, USA) – Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced it will be presenting at several upcoming scientific congresses in May and June.

Details of the presentations are as follows:

American Society of Cell and Gene Therapy (ASGCT) 24th Annual Meeting, May 11-14, virtual

Title: Changes in the Tumor Microenvironment in Patients with Glioblastoma Multiforme Treated with IFN-a Immune Cell & Gene Therapy (TEM-GBM_001 Study)
Type: Oral presentation
Time: Friday May 14, 1.30-1.45 PM CET

2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, virtual

Title: : A phase I-IIa study of genetically modified Tie-2 expressing monocytes in patients with glioblastoma multiforme (TEM-GBM Study)
Type: Poster presentation
Day: June 4

European Hematology Association (EHA) 2021 Virtual Congress, June 9-17, virtual

Title: A Phase I-IIA Study of Genetically Modified TIE-2 Expressing Monocytes in Patients with Glioblastoma Multiforme (TEM-GBM Study)
Type: Oral presentation
Time: Sunday June 13, 7.45-8.30 PM CET